Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
POET-DSM Advanced Biofuels was a joint venture between US-based POET and Netherlands-based Royal DSM, established to scale the production of cellulosic ethanol. The company utilized advanced biotechnology, including proprietary enzymes and yeast, to convert non-edible corn residue into biofuel. Their primary asset was 'Project Liberty,' a commercial-scale plant located in Emmetsburg, Iowa, which was designed to process 770 tons of corn stover per day. The venture represented a significant milestone in industrial biotechnology by demonstrating the conversion of agricultural waste into renewable energy at scale. In 2021, POET acquired DSM's interest in the venture, fully integrating the technology and operations into its own business.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on POET-DSM Advanced Biofuels.